Allergy Therapeutics plc (LON:AGY – Get Free Report) shares hit a new 52-week low during trading on Monday. The company traded as low as GBX 4 and last traded at GBX 4.47, with a volume of 150,247 shares. The stock had previously closed at GBX 4.50.
Allergy Therapeutics Stock Performance
The stock has a market capitalization of £294.15 million, a price-to-earnings ratio of -4.79, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83. The firm has a fifty day moving average of GBX 5.06 and a 200 day moving average of GBX 7.16. The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
See Also
- Five stocks we like better than Allergy Therapeutics
- The AI Buildout Is Only 15% Complete—Here Is Where the Next Dollar Actually Goes
- Cleared For Takeoff: Boeing’s 737 MAX 10 Approval Sets Up a Major Cash Flow Recovery
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
